Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhigang Peng

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Journal of Cancer|April 1, 2020
Effect of CELSR3 on the Cell Cycle and Apoptosis of Hepatocellular Carcinoma CellsZucheng Xie, Yiwu Dang, Huayu Wu, et al.
Nature Communications|June 24, 2026
Spatiotemporal flux breathing and topological sculpting in structured transverse orbital angular momentum latticesDawei Liu, Xingyuan Zhang, Yonghang Tai, et al.
Aging|February 6, 2020
Protein disulfide isomerases are promising targets for predicting the survival and tumor progression in glioma patientsZhigang Peng, Yu Chen, Hui Cao, et al.
Journal of Cancer|March 14, 2022
Erratum: Effect of CELSR3 on the Cell Cycle and Apoptosis of Hepatocellular Carcinoma Cells: ErratumZucheng Xie, Yiwu Dang, Huayu Wu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 9, 2010
Targeted agents for chronic myelogenous leukemia: will that be the end of allogeneic bone marrow transplantation for that disease?Yuzhen Liang, Yongrong Lai, Paul Schwarzenberger, et al.
Oncology Research|January 25, 2017
MicroRNA-148a Acts as a Tumor Suppressor in Osteosarcoma via Targeting Rho-Associated Coiled-Coil KinaseHaiYan Yang, ZhiGang Peng, ZhenZhen Da, et al.
American Journal of Hematology|May 30, 2026
Treatment Patterns and Clinical Outcomes After Immunotherapy Failure in Patients With Natural Killer/T-Cell LymphomaShenrui Bai, Yongping Song, Liang Wang, et al.
Cancer Immunology, Immunotherapy : CII|June 8, 2023
Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003)Yuankai Shi, Jie Cui, Hui Zhou, et al.
Journal of Hematology & Oncology|April 27, 2025
A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphomaHuangming Hong, Zegeng Chen, Mingzhi Zhang, et al.
American Journal of Hematology|August 27, 2021
Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: A multicenter studyYuchen Zhang, Shuyun Ma, Jun Cai, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Journal of Cancer|April 1, 2020
Effect of CELSR3 on the Cell Cycle and Apoptosis of Hepatocellular Carcinoma CellsZucheng Xie, Yiwu Dang, Huayu Wu, et al.
Nature Communications|June 24, 2026
Spatiotemporal flux breathing and topological sculpting in structured transverse orbital angular momentum latticesDawei Liu, Xingyuan Zhang, Yonghang Tai, et al.
Aging|February 6, 2020
Protein disulfide isomerases are promising targets for predicting the survival and tumor progression in glioma patientsZhigang Peng, Yu Chen, Hui Cao, et al.
Journal of Cancer|March 14, 2022
Erratum: Effect of CELSR3 on the Cell Cycle and Apoptosis of Hepatocellular Carcinoma Cells: ErratumZucheng Xie, Yiwu Dang, Huayu Wu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 9, 2010
Targeted agents for chronic myelogenous leukemia: will that be the end of allogeneic bone marrow transplantation for that disease?Yuzhen Liang, Yongrong Lai, Paul Schwarzenberger, et al.
Oncology Research|January 25, 2017
MicroRNA-148a Acts as a Tumor Suppressor in Osteosarcoma via Targeting Rho-Associated Coiled-Coil KinaseHaiYan Yang, ZhiGang Peng, ZhenZhen Da, et al.
American Journal of Hematology|May 30, 2026
Treatment Patterns and Clinical Outcomes After Immunotherapy Failure in Patients With Natural Killer/T-Cell LymphomaShenrui Bai, Yongping Song, Liang Wang, et al.
Cancer Immunology, Immunotherapy : CII|June 8, 2023
Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003)Yuankai Shi, Jie Cui, Hui Zhou, et al.
Journal of Hematology & Oncology|April 27, 2025
A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphomaHuangming Hong, Zegeng Chen, Mingzhi Zhang, et al.
American Journal of Hematology|August 27, 2021
Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: A multicenter studyYuchen Zhang, Shuyun Ma, Jun Cai, et al.
Pageof 7